FindTrial
Sign In

A Study to find the importance of genotyping in tacrolimus dose in kidney transplant patients

Precise Tacrolimus Dose Adjustments in Kidney Transplant patients from Industrial Workforce Considering CYP3A5 Genotyping Beyond Therapeutic Drug Monitoring - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/12/077751
Enrollment
16
Registered
2024-12-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: NIL: NIL

Sponsors

Imran Ahmed Siddiqui
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. ESIC Insured Patients who underwent kidney transplantation between Dec 2022 to April 2024 2. Received Kidney from live or cadaveric donors 3. Prescribed tacrolimus as immunosuprresant

Exclusion criteria

Exclusion criteria: 1. ESIC Insured patients who underwent any transplantation other than kidney 2. ESIC Insured patients from non-industrial workforce

Design outcomes

Primary

MeasureTime frame
Patients achieving target tacrolimus trough concentrations 7-10ng/mlTimepoint: day 6, 3rd month, 6th month—

Secondary

MeasureTime frame
1. To estimate the incidence of New Onset Diabetes Mellitus After Transplantation (NODAT) 2. Rejection episodes 3. Graft functionTimepoint: 1. at 6th month 2. in 6 months 3. Day 6, 3rd month and 6th month—

Countries

India

Contacts

Public ContactImran Ahmed Siddiqui

ESIC Medical College and Super Specialty Hospital

write2drimran@gmail.com9666913786

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026